Evolving immunotherapeutic solutions for triple-negative breast carcinoma

This publication has 105 references indexed in Scilit:

• Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
  JAMA, 2024
• Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer
  JAMA Oncology, 2024
• State Variation in Racial and Ethnic Disparities in Incidence of Triple-Negative Breast Cancer Among US Women
  JAMA Oncology, 2023
• Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors
  JAMA Oncology, 2022
• Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients
  Breast Cancer Research and Treatment, 2021
• Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
  JAMA Oncology, 2020
• EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo
  Clinical & Translational Immunology, 2020
• A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer
  Cancer, 2019
• Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
  JAMA Oncology, 2019
• Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
  Breast Cancer Research and Treatment, 2017